CHIME : Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner‐City Residents
Journal of Viral Hepatitis · 2025
DOI: 10.1111/jvh.70057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Brian Conway und 2 weiteren Autor:innen. Beteiligte Einrichtung: Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Sofosbuvir, Heterocyclic Compounds, 4 or More Rings, Carbamates, Antiviral Agents. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
The combination of Sofosbuvir/Velpatasvir(S/V) is approved for the treatment of chronic HCV infection. In registrational trials, cure rates of 95% or more were achieved when administered as one pill per day for a period of 12 weeks, regardless of genotype or disease stage. There is a need to develop and evaluate systems of care in populations excluded from clinical trials. We aim to evaluate the safety and efficacy of S/V in a prospective study of HCV‐infected inner‐city residents enriched for risk behaviours for non‐adherence to therapy, including problematic drug use and unstable housing. Through dedicated outreach events, we identified HCV‐infected patients who were not currently engaged in health care and who were eligible to receive government‐funded antiviral treatment for HCV infection. We offered them the opportunity to enrol in a multidisciplinary programme of care to address medical, psychological, social, and addiction‐related needs, and provide S/V therapy in this context, with enhanced supervision of adherence. We identified 222 eligible subjects, 31.5% female, median age of 47 (24–81) years. The most common genotype was 1, followed by 3 (48.2%, 38.7%) and 21.2% scored F3‐F4 FibroScan scores. 55.9% have unstable housing, and 98.6% are active drug users, with the majority utilising fentanyl, followed by amphetamines (82.9%, 64.9%). HCV treatment has been started in all 222 persons within a median of 6 weeks of engagement in care. 218 persons completed treatment, one individual withdrew from the treatment, and 3 overdose deaths were documented. HCV cure was documented in 211/218 (96.8%). Virologic relapse was documented in the other 7 cases. The intent‐to‐treat SVR rate of HCV treatment with S/V was 211/222 (95.0%). Taken together, our data validate the development of multidisciplinary programmes such as ours to address HCV infection, yielding high rates of engagement and retention in care, promoting initiation of treatment (usually within 6 weeks) and > 97% rate of cure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada.
- Simon Fraser University, Vancouver, British Columbia, Canada.
ORCID-Profile: Brian Conway, Shana Yi
Förderung
- Gilead Sciences
Zitieren
APA
Conway, B., Yi, S., & Truong, D. (2025). CHIME : Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner‐City Residents. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70057
Vancouver
Conway B, Yi S, Truong D. CHIME : Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner‐City Residents. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70057
BibTeX
@article{Conway2025,
author = {Conway, Brian and Yi, Shana and Truong, Daivd},
title = {CHIME : Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner‐City Residents},
journal = {Journal of Viral Hepatitis},
year = {2025},
doi = {10.1111/jvh.70057}
}
EUVIMED